Assessment of people living with chronic hepatitis B in Australia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The REACH-B study is an observational cohort study aimed at characterizing and monitoring the care and treatment needs of individuals living with chronic hepatitis B in Australia. Participants who have attended participating clinics for hepatitis B care within the last year will be enrolled, and data will be collected on demographics, laboratory parameters, liver disease assessment, treatment history, and clinical management. Follow-up data will be gathered at each visit or at least once a year to track treatment and disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. All individuals diagnosed with chronic hepatitis B in the participating study sites are eligible to be included (both newly diagnosed cases and those diagnosed in the past).
2. 16 years of age or older.
3. Attended the health service for HBV care within the prior 12 months from study commencement (retrospective recruitment) OR Attending the health service for HBV care from study commencement (prospective recruitment)

Exclusion Criteria:

1\. Nil

Where it's running

• St Vincent's Hospital
  Sydney, New South Wales, Australia Recruiting
• Justice Health and Forensic Mental Health Network
  Sydney, New South Wales, Australia Recruiting
• Blacktown Mount Druitt Hospital
  Sydney, New South Wales, Australia Recruiting
• Westmead Hospital
  Sydney, New South Wales, Australia Recruiting
• Menzies School of Health Research (Royal Darwin & Alice Springs Hospitals)
  Darwin, Northern Territory, Australia Recruiting
• Top End Medical Centre
  Darwin, Northern Territory, Australia Recruiting

Study contacts

• Principal investigator: Gail Matthews, PhD MBBS — Kirby Insitute, UNSW
• Study coordinator: Jessica Carter
• Email: jcarter@kirby.unsw.edu.au
• Phone: +61290654212

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Entecavir 0.5 mg vs 1.0 mg daily in adults with HBV-related decompensated cirrhosis

  This trial tests whether 0.5 mg or 1.0 mg of entecavir once daily can better lower HBV DNA in adults with HBV-related decompensated cirrhosis over 24 weeks.

  Recruiting Phase 4 Bangladesh Medical University · Dhaka, Dhaka Division · NCT07816094

• Hepatitis B in Zambia: an observational cohort of adults with HBV, with or without HIV

  This observational cohort follows adults diagnosed with hepatitis B in Zambia, with and without HIV coinfection, to see how their liver disease and HBV (and HIV when present) change over several years while they receive standard care.

  Recruiting at 3 sites University of Alabama at Birmingham · Lusaka and 2 other locations · NCT07589985

• Long-term outcomes of pegylated interferon alfa-2b in families with clustered hepatitis B and high risk of cirrhosis or liver cancer

  This study will try pegylated interferon alfa-2b to see if it improves long-term outcomes for people with chronic hepatitis B from families where cirrhosis or liver cancer affects two generations.

  Recruiting First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shaanxi and 1 other locations · NCT07079150

• Comparing two treatments to prevent hepatitis B transmission from mothers to infants

  This study is testing whether two different antiviral treatments can help prevent pregnant women with high hepatitis B levels from passing the virus to their babies.

  Recruiting Guangzhou 8th People's Hospital · Guangzhou, Guangdong and 9 other locations · NCT06947356

• Untreated or Unknown HBV, HDV, and HCV in South-East Austria: See if People Need Care

  This study looks at past test results to see how many people in South-East Austria have hepatitis B, hepatitis D coinfection, or hepatitis C that hasn’t been treated yet or isn’t known, and then invites them for care.

  Recruiting Medical University of Graz · Graz, Styra · NCT06834178

• Monoclonal antibody treatment for chronic hepatitis B

  This study is testing a new monoclonal antibody treatment for people with chronic hepatitis B to see if it can help clear the virus and possibly allow them to stop their long-term antiviral medications.

  Recruiting Phase 1 University of Aarhus · Aarhus N · NCT06668727

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.